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Summary. Fifty-seven cases of T-cell lymphomas (TCL) 
including 5 lymphoblastic (T-LBL) and 52 peripheral 
TCL (PTCL) were analyzed by immunohistochemistry 
for the expression of p53, mdm2, p21, Rb, cyclin DI, 
cyclin A, cyclin B1, and Ki67IMIB1 proteins and 39/52 
PTCL were also analyzed for the expression of p16 
protein and for the presence of apoptotic cells by the 
TUNEL method. The aim was to search for abnormal 
immunoprofiles of p53 and Rb growth control pathways 
and to determine the proliferative activity and the 
apoptotic index of TCL. Abnormal overexpression of 
p53, p21 and mdm2, in comparison to normal lymph 
nodes, was found in 12/57,10/57 and 2/57 cases of TCL, 
respectively. Abnormal loss of Rb and p16 expression 
was found in 1/57 and 2/39 cases, respectively, whereas 
abnormal overexpression of cyclin D1 was not detected 
in any of the 57 cases. Our data revealed entity-related 
p53/p21/mdm2 phenotypes. Indeed, most nodal and 
cutaneous CD30+ anaplastic large cell lymphomas 
(ALCL) showed concomitant overexpression of p53 and 
p21 proteins (718 cases), and mdm2 was overexpressed 
in 2 p53-positive nodal ALCL. In contrast, over- 
expression of p53 was found in 3/17 cases of nodal 
peripheral TCL unspecified (PTCL-UC) and 217 non- 
ALCL cutaneous pleomorphic TCL. Overexpression of 
p21 protein was detected in 213 p53-positive PTCLUC 
and in 112 p53-positive non-ALCL cutaneous 
pleomorphic TCL. Finally, al1 the remaining 25 cases of 
TCL did not show p53 and p21 overexpression. Overali, 
the p53+/p21+ phenotype in 10157 TCL suggests wild- 
type p53 capable of inducing p21 expression. The 
highest apoptotic index (Al) was found in ALCL and a 
positive correlation between apoptotic index and Ki67 
index (p<0.001) was detected. Ki67, cyclin A and cyclin 
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B1 expression was found in al1 57 TCL and on the basis 
of the combined use of these 3 variables, 3 groups of 
proliferative activity,.could be determined: a) high in 
ALCL and T-LBL, b) low in mycosis fungoides (MF) 
and y6 hepatosplenic TCL, and c) intermediate in the 
remaining TCL entities. The proliferative activity in the 
12 p53 overexpressing cases was higher in comparison 
to the 45 p53-negative cases. Ki67 expresion in more 
than 25% of tumour cells showed significant correlation 
with p53 overexpression (p<0.001). Rb expression 
tended to be parallel to Ki67, cyclin A and cyclin B1 
expression in al1 but one case of nodal PTCL-UC which 
displayed loss of RB expression. Interestingly, this case 
was p53-negative, whereas the p53-positive cases were 
Rb-positive. These findings suggest that different 
pathogenetic routes may function in some TCL, 
involving either the p53 or, less frequently, the Rb 
pathways. 
Key words: Cell-cycle proteins, Apoptosis, immuno- 
histochemistry, T-cell lymphomas 
lntroduction 
There is increasing evidence that deregulation of the 
p53lmdm21p21 and pl61Rb growth control pathways and 
impainnent of other components of the cell cycle such as 
cyclins, cyclin-dependent kinases (CDK) and cyclin- 
dependent kinase inhibitors (CDKI) may be involved in 
oncogenesis (Cordon-Cardo, 1995; Sellers and Kaelin, 
1997; Gillet and Barnes, 1998; Liggett and Sidransky, 
1998). 
P53 tumour suppressor gene is important for the 
control of cell death and proliferation, inducing cell 
cycle arrest andlor apoptosis in response to various 
cellular stress (Cox, 1997; Polyak et al., 1997). P-53 
dependent G1 arrest is mediated, at least in part, through 
p53-mediated induction of p21/WAF1/Cip17 an inhibitor 
of the cyclin-cyclin-dependent kinase (CDK) complexes 
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(Cox, 1997). The activity and the stability of p53 protein 
is regulated via interactions with proteins such as mdm2 
which allows targeting of p53 to the ubiquitin-mediated 
proteolytic network (Prives and Hall, 1999). Mdm2 
binding also blocks the ability of p53 to interact with the 
transcriptional apparatus and disruption of the p53- 
mdm2 interaction is likely to be associated with p53 
stabilization after cellular stress or oncogene imbalance 
(Haupt et al., 1997; Kubbutat et al., 1997; Save et al., 
1998; Prives and Hall, 1999). 
p53 gene mutations have been described in 
lymphoid malignancies, more frequently in Burkitt's 
lymphoma and in transformation of low to high grade B- 
cell lymphoma (BCL) (Cesarman et al., 1993; Sander et 
al., 1993; Du et al., 1995; Chilosi et al., 1996; Villuendas 
et al., 1997). Many studies reported a discordance 
between low rates of p53 gene mutation and frequent 
immunoexpression of the protein, which may reflect 
expression of a stabilized wild-type(wt) p53 protein 
(Matsushima et al., 1994; Chilosi et al., 1996; Maestro et 
al., 1997; Villuendas et al., 1997). In this respect, a 
combined immunohistochemical evaluation of p53 and 
p21 proteins could be helpful to obtain indirect 
information about the status of the p53 gene since only 
wt p53 can induce p21 protein (Chilosi et al., 1996). 
Although many p53 studies were performed in BCL, 
only a few studies have focused on p53 abnormalities in 
T-cell lymphomas (TCL). TCL constitute a 
morphologically and immunologically heterogeneous 
group of usually aggressive turnours, which represent 15 
to 20% of non-Hodgkin's lymphomas (NHL) (Harris et 
al., 1994; Gisselbrecht et al., 1998). In these tumours, 
overexpression of p53 protein is reported in 20-30% of 
cases, whereas mutations of p53 gene seem to be very 
rare (Cesarman et al., 1993; Inghirami et al., 1994; 
Kanavaros et al., 1994; Matsushima et al., 1994; 
Lauritzen et al., 1995; Pescarmona et al., 1999). 
A critica1 step in cell cycle progression is 
phosphorylation of the Rb protein (pRb) resulting in 
release of the E2F transcription factor which plays an 
important role in the regulation of S-phase entry 
(Weinberg, 1995). pRb phosphorylation is stimulated by 
cyclin-DlCDK4 complexes and inhibited by p16. P16 
functions as an inhibitor of CDK4. Therefore, p16, 
cyclin D1 and pRb are suggested to function in a single 
regulatory pathway of the cell cycle (Liggett and 
Sidransky, 1998). Unregulated phosphorylation of pRb 
by CDK4 due, either to cyclin-Dl overexpression or loss 
of functional p16 could lead to uncontrolled cellular 
proliferation. Moreover, there is recent evidence for a 
complex network linking directly the function of Rb and 
p53 genes via mdm2. Rb binding to mdm2 could 
overcome the antiapoptotic function of mdm2 on p53- 
induced apoptosis and could also inhibit the mdm2- 
targeted p53 degradation, but could not prevent mdm2 
from inhibiting the p53-mediated transactivation (Hsieh 
et al., 1999). With respect to lymphoid malignancies, 
alterations of p16 gene structure andlor expression have 
been reported more frequently in T-acute lymphoblastic 
leukaemias (T-ALL), in adult T-cell leukaemiasl 
lymphomas (ATLL) and in transformation of low to high 
grade B-cell lymphomas (Siebert et al., 1996; Herman et 
a1.,1997; Uchida et al., 1997; Drexler, 1998; Gerajts et 
a1.,1998; Villuendas et al., 1998). Abnormalities of the 
Rb gene expression have been described in some high 
grade B-cell lymphomas (Martinez et al., 1993; Weide et 
al., 1994; Zhu et al., 1995; Grierson et al., 1996; Jares et 
al., 1996). On the other hand, cyclins are important 
molecules for the progression of the cell cycle and are 
divided into two main families (Gillet and Barnes, 
1998). The G1 family includes cyclins C, DI-3 and E, 
which are important for the passage of cells through the 
G1 phase and their entry into the S-phase. The other 
family includes the mitotic cyclins A and B. Cyclin A 
plays a role in DNA replication in the S-phase. Cyclins 
B1  and B2, in conjunction with p34cdc2, ensure 
irreversible entry into mitosis. 
Prompted by the above data and because of the 
paucity of combined immunohistochemical information 
regarding cell-cycle regulation in TCL we have 
investigated proteins involved in the p53 and Rb growth 
control pathways in relation with the proliferation status 
as determined by the expression of Ki67, cyclin A and 
cyclin B1 proteins in 57 cases of TCL. The aims were a) 
to search for immunohistochemical abnormalities of the 
p53 or Rb networks, b) to determine the immunohisto- 
chemical proliferation status, and c) to correlate the 
findings with the histological subtypes of TCL. 
Materlals and methods 
Fifty-two cases of peripheral T-cell lymphomas 
(PTCL) and five cases of lymphoblastic T-cell 
lymphomas (T-LBL) were selected at initial diagnosis 
(Table 1). Al1 TCL cases with available tissue blocks 
were retrieved from the files of the Departments of 
Pathology of the University Hospital of Ioannina, the 
Evangelismos Hospital of Athens and the Venizelion 
Hospital of Heraklion. The TCL cases were selected on 
the basis that tumour cells expressed at least one of the 
CD3, UCHL-1/CD45RO T-cell antigens and were 
negative for the B-cell marker L26tCD20. Lymphomas 
were classified according to the REAL classification 
(Harris et al., 1994) (Table 1). Five reactive lymph nodes 
were included as control. 
lmmunohistochemical staining 
Immunostainings were performed on formalin-fixed, 
paraffin-embedded tissue sections by the alkaline- 
phosphataselanti-alkaline phospatase (APAAP) 
procedure with microwave pretreatment. Monoclonal 
antibodies directed against p53 protein (DO-7; Dako SA. 
Glostmp, Denmark; dilution 1:50), mdm2 protein (IF-2, 
Calbiochem NY, dilution 1:50), p2llwafl protein (EA- 
10; Calbiochem NY; dilution 1:50), Rb protein (Rbl 
Dako SA, dilution 1:20), cyclin D1 (DCS-6 Novocastra; 
dilution 1:20), proliferation-associated nuclear antigen 
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Ki67 (MIB-1: Immunotech, Marseille, France; dilution 
1:20), cyclin A (6E6, Novocastra; dilution 1:10), cyclin 
B1 (7A9, Novocastra; dilution 1:lO) and p16 (F-12, 
Santa Cruz; dilution 1:100) were applied. P16 was tested 
only in 39 cases of PTCL because of lack of material. 
Positive control slides were included in al1 cases. They 
consisted of reactive lymph nodes for Rb, cyclin A, 
cyclin B1 and Ki67, Hodgkin lymphoma known to be 
positive for p53 and mdm2 (Kanavaros et al., 2000) 
normal colon for p21 and breast carcinoma for cyclin 
DI. A semi-quantitative evaluation of p53, mdm2, p21, 
and cyclin D1 expression was performed, by using the 
x40 objective and counting at least 5 fields selected on 
the basis that they contained considerable numbers of 
immunopositive cells. P53, mdm2, p21 and cyclin D1 
abnormal overexpression was considered when more 
than 10% of tumour cells were positive since these 
proteins are either expressed at low levels or are 
undetectable in the 5 reactive lymph nodes. Thus each 
case was conventionaly scored by evaluating the 
percentage of positive tumour cells: 10 to 25%; 25 to 
50%; and more than 50%. For angioimmunoblastic 
lymphomas (AIL), since the neoplastic or reactive nature 
of the positive cells could not be ascertained, the 
quantification was assessed as the overall percentage of 
the positive cells. For Ki67, p16, Rb, cyclin A and cyclin 
B1, a continuous score system was adopted since the 5 
reactive lymph nodes always expressed Rb, p16, Ki67, 
cyclin A and cyclin B1. Then, the groups of positivity 
were determined as follows: less than 10%; 10 to 25%; 
25 to 50%; and more than 50%. Rb or p16 loss of 
expression was considered when there was no nuclear 
staining in the entire specimen (diffuse) or in areas 
(focal) of the tumour section. Staining of stromal and 
Table 1. Overexpression of p53, mdm2 and p21 proteins in relationship 
with the ciinicopathological entities of T-cell lymphomas (TCL). 
Precursor TCL 
T-LBL O15 011 5 015 
Nodal TCL 
AIL-TCL O19 O19 019 
PTCL-UC 3/17 O11 7 2/17 
ALCL nodal 515 2/5 515 
Ortranodal TCL 
MF 0/3 013 013 
ALCL cutaneous 2/3 2/3 
Non-ALCL cutaneous pleomorphic TCL 217 ln 
ETCL 011 011 011 
HPS y& TCL 011 011 011 
Other extranodal TCL* 016 O/s , 0/6 
TOTAL 12/57 2/57 10157 
T-LEL: T-lymphoblastic lymphoma; AIL-TCL: Angioimmunoblastic T-cell 
lymphoma; ALCL: Anaplastic large cell lymphoma; PTCL-UC: Peripheral 
TCL-unclassified; ETCL: Enteropathy-type intestinal T-cell lymphoma; 
HPS y8 TCL: Hepatosplenic y8 T-cell lymphoma; *: three cases with 
initial diagnosis in muscle tissue, 2 cases with initial diagnosis in 
adipose tissue and 1 case with initial diagnosis in tongue tissue. 
endothelial cells was required as internal positive control 
to interpret Rb or p16 loss of expression. A mosaic 
pattern with positive cells intermingled with negative 
cells was not considered as loss of expression since the 
leve1 of p16 protein varies along the cell cycle 
(Villuendas et al., 1998). 
TUNEL 
The TdT (terminal deoxynucleotidyl-transferase)- 
mediated in-situ labelling technique (TUNEL) (Apotag 
kit, Oncor, Gaithersburg) was carried out as previously 
described (Czader et al., 1996). Positive controls 
(reactive lymph nodes) and negative controls (sections 
without TdT) were included in every staining. 
Morphologically intact TUNEL-positive cells and 
apoptotic cells were considered as positive and are 
referred to as apoptotic cells. Necrotic areas were 
excluded. The number of apoptotic cells was recorded 
by using the x40 objective and by counting the apoptotic 
cells in 10 randomly selected fields, corresponding to a 
total of 2000 to 5000 cells. The apoptotic index (AI) was 
expressed as the mean number of labelled cells per 100 
intact cells. 
Statistical analysis 
Statistical analysis was performed using Chi-square 
test with Yates' correction. Fisher exact test was used 
when there were less than 5 cases in one group in a table 
for statistical analysis. Pearson and Spearman correlation 
analysis were used for the assessment of correlation 
between continuous variables. The results were 
considered as statistically significant when pc0.05. 
p53, mdm2 and p21 expression 
Our results showed that concomitant p53 and p21 
protein overexpression was strongly associated with 
nodal and cutaneous anaplastic large cell lymphoma 
(ALCL) while it was less frequent or absent in the other 
clinicopathological entities of TCL (Table 1). Mdm2 
overexpression was detected in only 2/57 cases of TCL 
which were nodal ALCL. In detail, nodal and cutaneous 
ALCL, showed concomitant overexpression of p53 in 
718 cases and the 2 mdm2-positive cases were also 
p53+/p21+ (Table 1) (Fig. 1). In nodal peripheral TCL 
unspecified (FTCL-UC) overexpression of p53 protein 
was found in 3/17 cases. P21 overexpression was 
detected in 2/17 cases which were also p53-positive. h 
non-ALCL cutaneous pleomorhic TCL, p53 over- 
expression was found in 217 cases and one of these 2 
cases also showed p21 overexpression. The lymphomas 
belonging to the other categories of TCL i.e. 9 AIL, one 
hepatosplenic ya, one intestinal enteropathy-type TCL 
(ETCL), 5 lymphoblastic T-celi lymphomas, 3 MF and 6 
other extranodal TCL (Table 1)  did not show any 
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significant overexpression of p53 and p21 proteins. 
Ki67, cyclin A, cyclin B1, cyclin D I ,  Rb and p 16 
expression 
Ki67, cyclin A and cyclin B1 expression was found 
in al1 57 TCL (Table 2) and on the basis of the combined 
use of these 3 variables, 3 groups of proliferative activity 
could be determined (with very rare cases being outside 
the following limits): a) high in ALCL and T-LBL (mean 
rate >25% for each variable), b) low in MF and y6 
hepatosplenic TCL (mean rate <5 % for each variable), 
and c) intermediate in the remaining TCL entities (mean 
rate 5-25% for each variable). In detail, Ki67 expression 
Table 2. Expression of p53, mdm2, p21, Rb, p16, cyclin Di ,  cyclin A, 
cyclin 81 and Ki67 proteins in T-cell lymphomas (TCL). 
<lo96 1 O-25% 25-50% >m% 
P53 8* 9 3 
P21 11* 10 
Mdm2 7* 2 
Rb 1 32 21 3 
P16U 19 17 3 
Cyclin D1 2* 
Cyclin A 15 31 11 
Cyclin 81 27 14 6 
Ki67 17 29 9 2 
*: these cases were not considered to overexpres the corresponding 
proteins; #: only 39 cases of PTCL were studied for pl6 expression. 
Two cases with 10-25% positive cells displayed focal loss of p16 
expression. 
varied from 2 to 51%. The highest expression was found 
in ALCL (mean rate 38.3%). In contrast, MF showed the 
lowest Ki-67 expression with mean rate 1.9%. Cyclin A 
(Fig. 2) and cyclin B1 expression (Fig. 3) increased in 
parallel to Ki-67 expression with positivity varying from 
2 to 36% (cyclin A) and 1 to 31% (cyclin Bl). The 
highest expression was found in ALCL (mean rates 31% 
for cyclin A and 24.8% for cyclin Bl). In contrast, MF 
showed the lowest cyclin A and cyclin B1 expression 
with mean rates of 1.4% and 1.1%, respectively. Rb 
diffuse or mosaic expression (Table 2) was found in al1 
but one TCL and tended to parallel Ki67, cyclin A and 
cyclin B1 expression. The highest Rb expression was 
found in ALCL (mean rate 47.4%). Loss of Rb 
expression with concomitant intermediate proliferative 
activity was found in one nodal PTCLUC. In AIL, Rb 
expression was found in the majority of larger cells 
whereas most small cells were Rb-negative. In MF and 
the hepatosplenic Ty6 case about 10% of tumour cells 
were Rb-positive but this was not interpeted as loss of 
expression because of the low proliferative activity of 
these tumours. Cyclin D1 overexpression was not 
detected. Of the 39 tested cases of PTCL, 1 case of nodal 
PTCL-UC and 1 case of non-ALCL cutaneous 
pleomorphic TCL, displayed focal loss of p16 
expression in areas composed mainly of large cells 
which showed increased proliferative activity. The focal 
absence of p16 expression in these 2 cases was 
interpreted as loss of expression because in reactive 
lymph nodes higher levels of p16 expression were found 
in those compartments where cell proliferation was 
increased. P16 diffuse or mosaic expression was found 
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in al1 the remaining 37 PTCL studied, comprising 4 
nodal and 2 cutaneous ALCL, 15 nodal PTCL-UC, 9 
AIL, 1 ETL, 3 non-anaplastic large cell cutaneous 
pleomorphic TCL, and 3 other extranodal PTCL. The 
highest p16 expression was found in ALCL (mean rate 
49.2%). 
Apoptotic index 
The group of 39 cases which was studied for p16, 
was also investigated by the TUNEL method and 
interpretable results were obtained in 35 of them (Table 
3). The 4 nodal and 2 cutaneous ALCL showed the 
highest apoptotic index, varying from 1.1 to 2.3. Of the 
remaining 29 cases, only 3 cases of nodal PTCL-UC and 
Table 3. Apoptotic index (Al) and Ki67 index in relationship to the 
dinicopathological entities in 39 cases of peripheral T-cell lymphomas 
(PTCL). 
Number Al M67 index 
ofcases Range Range 
Nodal TCL 
AIL-TCL 9 0.1-0.9 7.6-12.3 
PTCL-UC 16 0.4-1.7 1 1.3-39.5 
ALCL 4 1.1 -2.3 25.2-51 
Extranodal TCL 
ALCL cutaneous 2 1.2-1.3 25.7-45.6 
Non-ALCL cutaneous pleomorphic TCL 4 0.5-1.4 19.1 -35.8 
ETCL 1 0.4 24.4 
Other extranodal TCL* 3 0.6-0.9 16.839.7 
.............................................................................................................. . ..... . ..... 
Total 39 35# 39 
*: four cases were not interpretable 
1 case of non-ACL cutaneous pleomorphic TCL showed 
AI>l, whereas in the remaining 26 cases the A1 varied 
from 0.1 to 0.9. 
Comparison of abnormal P53 and Rb phenotypes with 
proliferation profile 
We have observed the following abnormal 
phenotypes: a) p53 overexpression (12 cases); b) Rb loss 
of expression (1 case); and c) P16 loss of expression (2 
cases). Phenotypes involving combination of the above 
abnormal patterns were not observed. Al1 the cases with 
the above abnormal phenotypes exhibited an 
intermediate to high proliferation profile. The mean rates 
of Ki67, cyclin A and cyclin B1 expression in the 12 
p53-positive cases were higher in comparison to the 45 
p53-negative cases. The Ki67 expression in more than 
25% of tumour cells showed statistically significant 
correlation with p53 overexpression (pe0.001) and Rb 
expression in more than 25% (pe0.001). 
Comparison between apoptotic index and M67 index 
A positive correlation was found between apoptotic 
index (AI) and Ki67 index (Pearson coefficient r=0.739, 
pe0.001 and Spearman coefficient r=0.655, p<0.001) 
(Table 3). There was a statistically significant correlation 
between AI>1 and p53 overexpression Opc0.001). 
Discussion 
Our results show that p53 overexpression in TCL is 
strongly associated with ALCL but it is sporadic or 
Expresston of Cydin A 
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absent in the other clinicopathological entities. In total, 
most ALCL (nodal and cutaneous) but only a proportion 
of nodal PTCL-UC, and non-ALCL cutaneous 
pleomorhic TCL show p53 protein overexpression. In 
contrast, p53 protein overexpression was undetectable in 
other histological subtypes such as T lymphoblastic 
lymphomas (T-LBL), AIL, MF, ETCL, other non- 
cutaneous extranodal PTCL and hepatosplenic T-y6 
lymphoma. The finding of p53 overexpression in most 
ALCL, but only in some nodal PTCL-UC and non- 
ALCL cutaneous pleomorhic TCL concurs with previous 
data and appears to be very rarely related to p53 gene 
mutations (Cesarman et al., 1993; Matsushima et al., 
1994; Lauritzen et al., 1995; Pescarmona et al., 1999). 
Thus, these tumours may display overexpression of the 
wild-type (wt) p53 protein pathway. To further test this 
possibility and on the basis of previous studies (Chilosi 
et al., 1996; Viliuendas et al., 1997), we have analyzed 
the expression of the wt p53-induced p21 protein, which 
blocks cell cycle progression at the G1 to S interface 
(Cox, 1997). In our study, p21 overexpression was found 
in al1 cases of ALCL displaying p53 overexpression. 
This suggests that the p53 protein is of wild type (wt) 
and could induce p21 expression, which may function as 
control of the tumour cell proliferation (Cox, 1997). The 
stabilization of transcriptionally active wt p53 protein 
could reflect impairment of the mdm2-dependent 
degradation of p53 and inhibition of the mdm2- 
dependent negative regulation of the transactivation 
activity of p53 (Hsieh et al., 1999). Impairment of the 
interaction between mdm2 and p53 can occur through a) 
covalent modifications of the proteins (Le. 
phosphorylation), and b) the induction and action of the 
protein ARF which is the product of the alternative 
reading frame of the p16 locus (reviewed in Prives and 
Hall, 1999). However, despite the very frequent 
overexpression of wt-p53 and p21 proteins in ALCL, the 
high proliferation rates of ALCL, as evidenced by the 
high Ki67 (MIB-l), cyclin A and cyclin B1 expression, 
suggest that the presumptive p53-induced p21-mediated 
growth arrest is impaired and somehow overridden in 
these tumours. The inability of p21 to induce growth 
arrest could be related to p21 gene structural 
abnormalities, but these are rare in human tumours and 
rather absent in lymphomas (Cox, 1997; Maestro et al., 
1997). Alternatively, the amount of p21 protein may be 
insufficient to inhibit the activity of the cdk4/cyclin D 
complex, since in vitro studies have shown that a low 
leve1 of p21 protein promotes the assembly of active 
kinase complexes, whereas at higher concentration it 
inhibits kinase activity (Labaer et al., 1997). 
Abnormalities in the cell cycle downstream the step of 
regulation of p21 could also be involved i.e. alteration of 
p21 targets as described in melanomas (Wolfel et al., 
1995). Interestingly, 2 cases of ALCL with concomitant 
p53/p21 overexpression, also showed mdm2 
overexpression, in keeping with previous studies 
comprising a few ALCL (Martinez et al., 1995; Tzardi et 
al., 1996). Despite its overexpression, mdm2 does not 
seem to inhibit the p53-mediated transactivation, in view 
of the p53+/p21+ phenotype. However, in these 2 cases, 
the increased amounts of mdm2 rnight be sufficient to 
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induce functional inactivation of pRb despite its normal 
immunohistochemical expression, since mdm2 is able to 
interact physically and functionally with Rb protein 
(Xiao et al., 1995). This could be an additional hit for 
uncontrolled cell proliferation. 
Besides their high proliferative activity, ALCL in 
our study were also characterized by increased numbers 
of apoptotic cells in comparison to other PTCL, as 
evidenced by the TUNEL method. This suggests a 
tendency for positive correlation between apoptosis and 
proliferation, which was confirmed in the 35 studied 
PTCL of our series. This tendency probably reflects a 
general phenomenon in tumours and implies that 
apoptosis and proliferation are inseparable events during 
tumour growth (Du et al., 1996; Kiberu et al., 1996). 
Thus, it is possible that in ALCL, the presumptive 
inability of the overexpressed wt p53 protein to induce 
cell cycle arrest may, altematively, lead to activation of 
the p53-induced apoptotic program (Cox, 1997). This 
may result, at least in part, from p53-induced 
upregulation of the proapoptotic bax protein and the 
downregulation of the antiapoptotic bc12 protein.The 
findings of Schlaifer et al. (1996) in ALCL might 
support this assumption. It is possible that the ratio of 
p53/p21 protein levels plays a role in the cellular 
decision to arrest or to die but there is some evidence 
that apoptosis is dominant over cell-cycle arrest 
irrespective of p21 levels (reviewed in Cox, 1997). 
While al1 p53-positive ALCL were also p21- 
positive, 1 nodal PTCGUC and 1 non-ALCL cutaneous 
pleomophic TCL were p53-positivelp21-negative, 
suggesting functional inactivation of overexpressed p53 
unable to induce p21 expression in these 2 tumours 
(Cox, 1997). One hypothesis is p53 gene mutations but 
they are very rare in PTCL. Another hypothesis is 
inhibition of wt p53 protein-mediated transactivation by 
basa1 levels of mdm2 protein undetectable by 
immunohistochemistry. Indeed, the p53-mdm2 binding 
prevents p53-mediated transactivation but if the pRb, 
which is normally expressed in the above 2 cases binds 
to mdm2, then the mdm2-induced degradation of p53 
can be inhibited (Hsieh et al., 1999). 
In our study, Rb expression tended to parallel Ki67, 
cyclin A and cyclin B1 expression in al1 but one case of 
nodal PTCL-UC. This tendency suggests that Rb 
expression foilows the proliferative activity, representing 
a growth inhibitory response to control ceil proliferation, 
but it is necessary to determine the pRb phoshorylation 
status in TCL. Analogous findings of parallel pRbKi67 
expression have been previously reported in B-cell 
lymphomas (BCL) (Martinez et al., 1993; Jares et al., 
1996). We found loss of Rb expression concomitant with 
intermediate proliferative activity in only one nodal 
PTCL-UC. Our findings showing 105s of Rb expression 
in about 6% (1117 cases) of nodal PTCL-UC are 
somewhat different from those of Pescarmona et al. 
(1999) who analyzed only nodal PTCL-UC and reported 
such a loss in about 20% (10145 cases) of them. Case 
selection could be an explanation for this difference. We 
have then analyzed the expression of cyclin D1 and p16 
proteins which are involved in the cyclin Dl/pl6/Rb 
growth control pathway (Liggett and Sidransky, 1998). 
While no overexpression of cyclin D1 was detected in 
the 57 cases of TCL, 2/39 tested cases of PTCL dislayed 
focal loss of p16 expression. This is in keeping with the 
findings of Villuendas et al. (1998), who described a 
focal loss of p16 expression in 7/14 PTCL. Pinyol et al. 
(1998) reported loss of p16 expression in 2 studied 
ALCL with concomitant hypermethylation in one of 
them. Regarding molecular mechanisms, Martinez- 
Delgado et al. (1997) reported hypermethylation of p16 
gene in 3/20 TCL, al1 cases being of high-grade 
histology. Baur et al. (1999), reported hypermethylation 
of p l 6  gene in 117 PTCL and 1/2ALCL with 
concomitant absence of gene expression, assessed by 
RT-PCR, in this latter case. However, Otsuki et al. 
(1995) reported no deletion or mutation of p16 gene in 
35 PTCL. In the review of Drexler (1998), 471332 
mature TCL showed p16 deletions, but 44 of them were 
ATLL while none of the 27 PTCL showed p16 deletions. 
Taken together, the above findings indicate that a) loss of 
p16 expression is not frequent in PTCL, and b) 
hypermethylation of p16 gene may be the principal 
mode of p16 inactivation in PTCL whereas neither 
deletions nor mutations appear to be relevant 
mechanisms of p16 silencing in these tumours. Further 
combined immunohistochemical and molecular 
investigations are required to determine the p16 status in 
PTCL. 
Interestingly, the 2 cases of our study, with focal loss 
of p16 expression had neither loss of Rb expression nor 
p53 overexpression. Moreover, the one case with loss of 
Rb expression was p53-negative and the 12 p53-positive 
cases were Rb-positive. These findings suggest that 
different pathogenetic routes may function in some TCL, 
involving either the p53 or, less frequently, the Rb 
pathways. 
The comparison of TCL with B-cell lymphomas 
(BCL) reveals the following points with respect to the 
abnormalities of p53 and Rb pathways. 1) The p53/p21 
pathway is afFected in a proportion of "high-grade" BCL, 
more frequently in cases of tumour progression from 
"low-grade" BCL, where p53 overexpression is 
frequently associated to p53 gene mutations. In TCL, 
abnormalities of the p53 pathway are rare except for 
ALCL and they are not associated to p53 gene mutations 
(Matsushima et al., 1994; Villuendas et al., 1997; 
Pescarmona et al., 1999). 2) The Rb/pl6 pathway is 
affected in a substantial proportion of "high-gradelBCL, 
more frequently in cases of tumour progression from 
"low-grade" BCL, where loss of p16 expression is 
frequently associated to hypermethylation of the p16 
gene. In TCL, abnormalities of the RbP16 pathway are 
relatively uncommon but when loss of p16 expression 
occurs, is also frequently associated to hypermethylation 
of the p16 gene as in BCL (Weide et al., 1994; Martinez- 
Delgado et al., 1997; Villuendas et al., 1998; 
Pescarmona et al., 1999). Regarding lymphoid 
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leukaemias, abnormaiities of the p53 pathway (i.e. p53 
gene mutations) were detected in a proportion of B and 
pre B-cell acute lymphoid leukaemias (ALL) but not in 
most T-ALL (Prococimer and Rotter, 1994). In contrast, 
the p16 gene was frequentiy deleted in T-ALL (>50%) 
and in precursor B-ALL (>30%) but rarely in chronic 
lymphoid leukaemias (CLL); inactivation of the Rb-1 
gene is rare in ALL and CLL but loss of Rb protein 
seems to be more frequent (Hangaishi et al., 1996; 
Sellers and Kaelin, 1997; Drexler, 1998). 
In our study Ki67, cyclin A and cyclin B1 
expression was found in al1 57 TCL and on the basis of 
the combined use of these 3 variables, 3 groups of 
proliferative activity could be determined: a) high in 
ALCL and T-LBL; b) low in MF and y8 hepatosplenic 
TCL; and c) intermediate in the remaining TCL entities. 
Anaiogous findings in a series of lymphomas including 
cases of TCL were recently reported by Leoncini et al. 
(1999). Interestingly, we observed that the 12 cases with 
p53 overexpression exhibited higher proliferation 
activity than the 45 cases without p53 overexpression. In 
addition, the Ki67 expression in more than 25% of 
turnour cells showed statistically significant correlation 
with p53 overexpression @<0.001). This concurs with a 
previous study (Pescarmona et al., 1999), and provides 
further support for the hypothesis that p53 growth 
control pathway is impaired in this subset of TCL. 
In summary, the unique findings to T-cell 
lymphomas were that ALCL represent a lymphoma 
strongly associated with overexpression of p53 and p21 
along with high proliferative activity, elevated apoptosis 
and high pRb and p16 expression. This suggests: a) 
impairement of the wild-type p531p21 protein pathway, 
unable to induce cell-cycle arrest, but possibly able to 
increase apoptosis, and b) normal expression of the 
RbIpl6 pathway in relation to the proliferative activity 
of tumour cells. P53 and p21 overexpressions were 
sporadic or absent in the other entities of TCL. Mdm2 
overexpression does not appear to play a prominent role 
in TCL. Overall, immunohistochemical abnormalities of 
the Rb/Pló/Cyclin D1 pathway were not frequent in our 
series of TCL. Rb protein was normally expressed in 
relation to the proliferative activity of tumours in ail but 
one case of TCL and p16 protein expression was focally 
lost in U39 PTCL studied. This suggests involvement of 
the abnormal Rb or p16 expression in the pathogenesis 
of a few TCL. 
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